FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

Submitted by admin on May 20, 2022 - 10:28am
Source: 
Benzinga
News Tags: 
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death
Headline: 
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
snippet: 

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).

Do Not Allow Advertisers to Use My Personal information